[Results of an open study and a controlled comparative study of feprazone and naproxen in patients with rheumatoid arthritis or osteoarthrosis (author's transl)].
The so-called non-steroid antirheumatics have considerable significance in medical armamentarium for controlling polyetiological complexes of diseases. The numerous new developments are designed to reduce the side effects, some of which seem inevitable with increased efficacy. In this two-part study the authors deal with the new Feprazone. Prior to a double-blind randomized comparative study against Naproxen, an open study on effect and tolerance was performed in ten rheumatic patients over three months. In the second part a controlled study was carried out in 30 patients for four weeks following this treatment. The patients half of whom were each given 600 mg Feprazone or 750 mg Naproxen showed a definite improvement in the rheumatic symptoms as compared with their initial situation. A difference in therapeutic efficacy and tolerance was only noticeable in a slight trend in favour of Feprazone.
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D011298:Feprazone / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D010653:Phenylbutazone / Q000031:analogs & derivatives*
D009288:Naproxen; D011298:Feprazone; D010653:Phenylbutazone
Ergebnisse einer einfach offenen sowie einer kontrollierten Vergleichesstudie mit Feprazon und Naproxen bei Polyarthritis- und Osteoarthrose-Patienten.